{"name":"Actuate Therapeutics Inc.","slug":"actuate-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Gemcitabine - 21 day cycle","genericName":"Gemcitabine - 21 day cycle","slug":"gemcitabine-21-day-cycle","indication":"Pancreatic cancer","status":"phase_2"},{"name":"Gemcitabine - 28 day cycle","genericName":"Gemcitabine - 28 day cycle","slug":"gemcitabine-28-day-cycle","indication":"Pancreatic cancer","status":"phase_2"}]}],"pipeline":[{"name":"Gemcitabine - 21 day cycle","genericName":"Gemcitabine - 21 day cycle","slug":"gemcitabine-21-day-cycle","phase":"phase_2","mechanism":"Inhibits DNA synthesis by inhibiting ribonucleotide reductase and DNA polymerase alpha","indications":["Pancreatic cancer","Breast cancer","Non-small cell lung cancer"],"catalyst":""},{"name":"Gemcitabine - 28 day cycle","genericName":"Gemcitabine - 28 day cycle","slug":"gemcitabine-28-day-cycle","phase":"phase_2","mechanism":"Inhibits DNA synthesis by inhibiting ribonucleotide reductase and DNA polymerase alpha","indications":["Pancreatic cancer","Breast cancer","Non-small cell lung cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxNTjZEMWxJMXlOUkpFLVRGcmxnVjA0TVNaRWJ2ZTlKbmtfa2otRzdOb2JJSUNrQXpXZy1pWGhtS2JiNl8wV1VDeXpPLWh2eE1RTDlUQzRjRlB4ajJ2cUhvZ2dwSV9aYzhZM3ZGeWkyQ3Q4UFpaX05BMW8yWVJmQ2JuMzRoRW1fZ2dQbDBHd3NVRFdjY01kSENqRjNKOVhFWVRBcm5KY3dRRWxIVWx4VFlJcm95aGtLZnhmOFFTejE0MF8yOWY3RVdUMGlPMlJoYWRxSG1LbnlDZnBVX2w2OVNfRDJkVTV3UFZaaUlnNU12cTg5aVNNZzFOMXNqSzlwamd4ZERURWVn?oc=5","date":"2026-03-24","type":"pipeline","source":"BioSpace","summary":"Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers - BioSpace","headline":"Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxPS2RrMGt4Zm9YQjJudlV4cV9wcEdtMEhmUEJGR2IyYTBsV1VWbXpMWjhjdEpUclJFQ1hzM003UExsWWtlTkFGRVo5aXRVdGY5WWZNbUk0SF82STVKOURRazlLaklEdGVqdy1vU3drQ1pwUHBPNndVWWJ3cDNtSVlkZkM0VlYxYjNvTk00dGxTUnNHQzgtSDN3cnA2aDhyOWZEeWNxMTRJS2tsTFRvdGFPQUlQUjJCLU1UQTZtUDYtLVluZzBYS0NEUXY4eHljOTgtdEcyX1NlS1RoOTlwZzl5SnhfSlpjQjFzM2ktUnBUSDZCeFI3RzZldkZzTHRUbGM?oc=5","date":"2026-02-24","type":"pipeline","source":"GlobeNewswire","summary":"Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewswire","headline":"Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTFBxcXUwQ3dKQjZDbXk3Rnp5T0RldnBVN0JRbzR3ZGc5aFhXbFp3OHJHQUJKM0xMNFN1Zmxwb1oyWDB0dVFRck5HLW1SXzU1R3kzVlV0VzVR?oc=5","date":"2026-02-14","type":"pipeline","source":"Stock Titan","summary":"ACTU Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan","headline":"ACTU Financials: Income Statement, Balance Sheet & Cash Flow","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNUEVOOEg4ZmRtMTRSczh0dTZndVdSRDYxQTNaUVZBeHpxaHhMT1E1TG1ZZl9aVHNCY0FrZXdRcUZaQkRjOVAyQmVOaDdsR054U1B0NVVoaEdFb1VzYTBBbFFNNDkzME1pM21pQ0JkcHh6M3F3ejVtc0NWZGVWWkhFcGpjQmd3SXh2cElnakpFZXdxX3llTGdzWmRTTEhDZ1NXNXpFdElXQVVoZ05nTlE?oc=5","date":"2026-02-05","type":"pipeline","source":"Clinical Leader","summary":"Becoming A Backbone Therapy: Lessons Learned With Actuate Therapeutics - Clinical Leader","headline":"Becoming A Backbone Therapy: Lessons Learned With Actuate Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgJBVV95cUxQRFhQZl9qN1o2UEZGU0xHRzd5TDJKeXdYTmxRcjBYM1F1a2NUTXpPY0VhdVRqN2NCaENGeWp4dC1mYWExRGx4dExnU0RJczVwUVMzaVJYRW1NMUExb0g1U09MbVBqOWd4TlVmdUVGRjBocDF5NjlqMnp0U3d6ZDlweEFsTV9IUENTTHdsU0tXTVFLZGsxSmp1S0c5ZU5IenJleWVvbHoyZGdJMHE3M2ZTRXZTUXVIb2RsNXBzbk9sNGJHRGtNQWJvY0dTLVFGWTk2WHdkSi1ucXlEQjQ0VE1VMEc4NXdVMjVrazZ6Z3FhTW1salVTcFBlOXVWVDlfR1lFSUZ6V2JiUk0ycHI1eXJ6TkZyT3dnU0wxclNzS1lUbzRJSDI3dXNsNEluZE45LTJ1b3lOYmFoVlJtTHFmaEJPNmlR?oc=5","date":"2026-01-21","type":"trial","source":"GlobeNewswire","summary":"Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers - GlobeNewswire","headline":"Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPQkV4T3ZKcXRMRHZYdFYtOUpkX3Q2TzZlZGk4dXdZcENBcnk2YnVnX3FQU3lmNVJBblBhTEtLSTZVNURLWWZLdmJtdllMOUVkSUtiVVBaN1VXMTRVV1RMSGpsWE5uTjdxc1IwVTBwQW9fWlRUMmpqXzlWQmljZ0VBRmREeDZ4ZHkzRHhfTXNHYVdiUQ?oc=5","date":"2026-01-12","type":"trial","source":"Yahoo Finance","summary":"Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metast","headline":"Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQcXdKWHVUQlUzNXJLUFBIWHpjVml5ejBKSzRmNUZQOGtoeFdPSmlDbU9uX3A3eUVyUm94S3FETGlwNWYwSTl3b3U1TTd0N25XZ2tEN094ekZfUHJHRWFQMXFPb3V4Um5JZXVWOGpmcVFzODk4aW1PdGltVGhuNkJVQ2xkSlc1QktWQW1pSnFHcktZMDdPQUZMNEs3cTVVWElwaWdfaDhLemZtZnNXdEpqZWw5UWZpLWliNDFIdXBrTQ?oc=5","date":"2026-01-06","type":"trial","source":"Stock Titan","summary":"Experimental drug shrinks tough childhood tumors in early trial - Stock Titan","headline":"Experimental drug shrinks tough childhood tumors in early trial","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-27","type":"pipeline","source":"simplywall.st","summary":"Actuate Therapeutics, Inc.'s (NASDAQ:ACTU) market cap surged US$24m last week, private equity firms who have a lot riding on the company were rewarded - simplywall.st","headline":"Actuate Therapeutics, Inc.'s (NASDAQ:ACTU) market cap surged US$24m last week, private equity firms who have a lot ridin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxPMzhWWjdzNzNfRGpFVE1Hbjg3ckFqZEJZNEI5QUhtWVk4dnhEYlNZaTNxeTg0czRrUlZ3a2F5LUxHNWpVcU05NjlwMHVtYV81N2V6Vmg1U3hTdi1KTHBOdm9KaHZWUW5FVXBUWFdhbU5sMWl6ck5LSjJUWW44T2IzVy00QlNlM2ZvWE1IYnh6MnI3UW53OE1PcVp4RlFWYmtHYXJuNnBNZGNPMXQ4TVU1Z3hDMGo4N0daQVBGYWppbTd2Y2tTajlwTmJ3bW9XN1BGaG81aDhRSTAtYkRRVmlZMzhEYS1sb05HcUxWRjJSSGlrRmZTTnY5RWFxbDRPQzhLRXl0TXhQcmw1NUYyWFo5V1dVQkpPem03a0NBc29CVTQ5cFdCblctRU9PMWZrZWp6dEE?oc=5","date":"2025-09-11","type":"pipeline","source":"GlobeNewswire","summary":"Actuate Therapeutics Announces Closing of $17.25 Million - GlobeNewswire","headline":"Actuate Therapeutics Announces Closing of $17.25 Million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxOY3U1aVUzUWpqaVdZUnBFMjlZb3NFajVEcnVsSkp2QWpVZkp4alVXVW1wb1lZZGw3RWlJSTV3V0tmZFdnQVJ2b3BUUFV5MEh2bjBuYWctcVRzVFpydjlwVVRQM3RlaEt6VmtHZ0tfMU45aVdwc2p3bV9lSkdoVjM3VTRvc0FOUVNWeEZnV2pJRjhWSTFOWjlXSWs4RTYxVHRTWjRMNGY4Yk16VnJzZjN6ZHBlWEtFOUpaZXRRZ1NYNVhpal9MM2FIME5oU1RDM0JpdF9UNktaQ0U3SmFvb3hKWTFra21BQ3RQSTBqZmJHRQ?oc=5","date":"2025-09-10","type":"pipeline","source":"GlobeNewswire","summary":"Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock - GlobeNewswire","headline":"Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxNZTFLSG0wTlBQWUR1MllRcVpXMmlIU2lnejhIaDlMSkFINWVpazAtS1Y2cjlrUVlPTXJTel9Yb0RNcGlLS2NmWVp5aTc5OFNfYzZtRjlYRnVDQlc0SlFzWU9KZjBiQ1NzM2NUenNQdHFJeERwWHBJdmIwN0IzVWhNOEZ5MS0zUkRXUTVvVVNaMFhfbEk3aF93aVBiRjMzQXBWX3FYRXhlVWZYeEs5dnBvNXA3cWpZUUtqYWNFblNmZEJPdjdyVEhVX200OFdMc1E5ZjJkLWpWU2l6Q0Nob3N1a0taZ1g3QUpFTUE4STN3QmpwRUlWMTlfTjl0blA?oc=5","date":"2025-08-28","type":"pipeline","source":"prnewswire.com","summary":"GSK 3 Inhibitor Market Landscape Shows Promising Upswing as Growing Interest in Targeted Therapies | DelveInsight - prnewswire.com","headline":"GSK 3 Inhibitor Market Landscape Shows Promising Upswing as Growing Interest in Targeted Therapies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPMG5TeUtwb1ItX3VpS3J4RWZKYzl2RERkY1hBRXhCb010SEZhTEs0U3Z2RllYV0U2NjVERWtOdzhaX3p1MXBKX0M4dmlwbGUzT2Z1UjExUGFXRWlfaGZPVzdCSG1mSDl1Y3RoWHBBYWQ0cHFHTVQxSlV3SktDa3FWX2xfck4?oc=5","date":"2025-01-08","type":"regulatory","source":"Pharmaceutical Technology","summary":"Actuate’s pancreatic cancer therapy gains EMA OMPD - Pharmaceutical Technology","headline":"Actuate’s pancreatic cancer therapy gains EMA OMPD","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}